Bafna Pharmaceuticals Limited — Board Meeting, 11-11-2024: Outcome of Board Meeting

The Board of Bafna Pharmaceuticals has approved the unaudited financial results for the quarter and half-year ended September 30, 2024. Key highlights include total income of ₹413.46 crore, with a profit before tax of ₹2.62 crore. The company reported total expenses of ₹387.28 crore, showcasing an increase in operational efficiency compared to previous periods. This outcome reflects a positive trajectory in revenue, signaling a potential recovery from prior losses. The meeting concluded with the management indicating confidence in future performance along with strategies for growth.